Activity Description

In 2016 Renal Cell Carcinoma (RCC) was one of the top ten cancers diagnosed in
the United States. RCC is usually diagnosed in people greater than 50 years of age
with a slightly greater incidence in men than in women. This activity will review
the treatment options for patients with metastatic RCC. The pharmacological treatments
available, appropriate use, adverse events, monitoring of agents, and management of
adverse events will also be discussed. Future therapies and emerging agents will also
be explored.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion
of this activity, participants will be able to:

Faculty

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants the existence of any significant financial interest or any other relationship
with the manufacturer of any commercial product(s) discussed in an educational presentation.
Dr. McBride has served as a consultant/speaker for Amgen and Hospira.

Please note: The opinions expressed in this activity should not be construed as
those of the CME/CE provider. The information and views are those of the faculty through
clinical practice and knowledge of the professional literature. Portions of this activity
may include unlabeled indications. Use of drugs and devices outside of labeling should
be considered experimental and participants are advised to consult prescribing information
and professional literature.

CE Accreditation

Release Date: 03-11-2017
Expiration Date: 03-11-2020

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the National
Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation
Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE
Universal Activity Number 0221-9999-19-094-H01-P has been assigned to this knowledge-based,
home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU)
in states that recognize ACPE providers. Completion of an evaluation and post-test
with a score of 70% or higher is required to receive CE credit. Proof of completion
will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Funding

No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.